BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37965255)

  • 1. Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort.
    Huang J; Xia M; Liu R; Wang S; Duan X; Peng J; Li E; Zhou Y; Li C; Zhang Q; Tian J; Wang X; Su Z; Tan J; Peng B; Zhang J; Li J; Dai L; Lei M
    Front Cell Infect Microbiol; 2023; 13():1288914. PubMed ID: 37965255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
    Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants.
    Qu P; Evans JP; Kurhade C; Zeng C; Zheng YM; Xu K; Shi PY; Xie X; Liu SL
    mBio; 2023 Feb; 14(1):e0317622. PubMed ID: 36625591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Clinical Outcomes and Imaging Features in Hospitalized Patients with SARS-CoV-2 Omicron Subvariants.
    Lee JE; Hwang M; Kim YH; Chung MJ; Jeong WG; Sim BH; Jeong YJ
    Radiology; 2023 Jul; 308(1):e230653. PubMed ID: 37462497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated antigen assays display a high heterogeneity for the detection of SARS-CoV-2 variants of concern, including several Omicron sublineages.
    Osterman A; Krenn F; Iglhaut M; Badell I; Lehner A; Späth PM; Stern M; Both H; Bender S; Muenchhoff M; Graf A; Krebs S; Blum H; Grimmer T; Durner J; Czibere L; Dächert C; Grzimek-Koschewa N; Protzer U; Kaderali L; Baldauf HM; Keppler OT
    Med Microbiol Immunol; 2023 Oct; 212(5):307-322. PubMed ID: 37561226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization.
    Morris CP; Eldesouki RE; Sachithanandham J; Fall A; Norton JM; Abdullah O; Gallagher N; Li M; Pekosz A; Klein EY; Mostafa HH
    Clin Infect Dis; 2023 Apr; 76(7):1276-1284. PubMed ID: 36366857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of multiplex allele-specific RT-qPCR assays for differentiation of SARS-CoV-2 Omicron subvariants.
    Li J; Cheng R; Bian Z; Niu J; Xia J; Mao G; Liu H; Wu C; Hao C
    Appl Microbiol Biotechnol; 2024 Dec; 108(1):35. PubMed ID: 38183475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
    Feikin DR; Higdon MM; Andrews N; Collie S; Deloria Knoll M; Kwong JC; Link-Gelles R; Pilishvili T; Patel MK
    Vaccine; 2023 Mar; 41(14):2329-2338. PubMed ID: 36797097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
    Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
    Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
    Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
    JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion.
    Hossain A; Akter S; Rashid AA; Khair S; Alam ASMRU
    Microb Pathog; 2022 Sep; 170():105699. PubMed ID: 35944840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population-based cohort study in British Columbia, Canada.
    Russell SL; Klaver BRA; Harrigan SP; Kamelian K; Tyson J; Hoang L; Taylor M; Sander B; Mishra S; Prystajecky N; Janjua NZ; Zlosnik JEA; Sbihi H
    J Med Virol; 2023 Jan; 95(1):e28423. PubMed ID: 36546412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
    Xia S; Wang L; Jiao F; Yu X; Xu W; Huang Z; Li X; Wang Q; Zhu Y; Man Q; Jiang S; Lu L
    Emerg Microbes Infect; 2023 Dec; 12(1):2178241. PubMed ID: 36748716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.
    Nakakubo S; Kishida N; Okuda K; Kamada K; Iwama M; Suzuki M; Yokota I; Ito YM; Nasuhara Y; Boucher RC; Konno S
    Lancet Infect Dis; 2023 Nov; 23(11):1244-1256. PubMed ID: 37399831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of novel SARS-CoV-2 rapid antigen tests in the era of omicron outbreak.
    Widyasari K; Kim S
    PLoS One; 2023; 18(8):e0289990. PubMed ID: 37561721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.
    Qu P; Evans JP; Faraone J; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    bioRxiv; 2022 Oct; ():. PubMed ID: 36299423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
    Tamura T; Yamasoba D; Oda Y; Ito J; Kamasaki T; Nao N; Hashimoto R; Fujioka Y; Suzuki R; Wang L; Ito H; Kashima Y; Kimura I; Kishimoto M; Tsuda M; Sawa H; Yoshimatsu K; Yamamoto Y; Nagamoto T; Kanamune J; Suzuki Y; Ohba Y; ; Yokota I; Matsuno K; Takayama K; Tanaka S; Sato K; Fukuhara T
    Commun Biol; 2023 Jul; 6(1):772. PubMed ID: 37488344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Identification of SARS-CoV-2 Omicron BA.5 Spike Mutation F486V in Clinical Specimens Using a High-Resolution Melting-Based Assay.
    Aoki A; Adachi H; Mori Y; Ito M; Sato K; Kinoshita M; Kuriki M; Okuda K; Sakakibara T; Okamoto Y; Jinno H
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
    Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization.
    Morris CP; Eldesouki RE; Sachithanandham J; Fall A; Norton JM; Abdullah O; Gallagher N; Li M; Pekosz A; Klein EY; Mostafa HH
    medRxiv; 2022 Sep; ():. PubMed ID: 36172137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.